BRANFORD, Conn. / Mar 15, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2023, and provided a business update.
FY 2023 and Recent Business Highlights
“Throughout 2023 and now into 2024, Azitra's unwavering commitment to combatting multiple serious skin conditions and diseases has propelled the company towards fundamental near-term catalysts,” said Francisco Salva, CEO of Azitra. “For our leading program, ATR-12 targeting Netherton’s syndrome, we've transitioned into the operational phase for our Phase 1b clinical trial. With a CRO onboard and discussions finalized with lead sites to activate the program and recruit ~12 patients, we're poised to execute on a series of potentially high-impact catalysts. Moving forward, we're focused on executing on key value-driving milestones, including getting the first patient enrolled, and a release of initial clinical data.”
“Next, for our ATR-04 program targeting EGFRi-associated rash, we intend to submit an IND for a Phase 1b clinical trial in cancer patients undergoing EGFRi targeted therapy in mid-2024. Subject to FDA clearance of our IND, we plan to initiate a Phase 1b clinical trial by year end.
“Additionally, regarding our Joint Development Agreement with Bayer, we are pleased with the recent progress of our collaboration and Bayer’s re-affirmed commitment to an execution of a license agreement.”
Pipeline and Upcoming Milestones
Financial Results for the Year Ended December 31, 2023
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the presentation of data from the Phase 1b study of ATR-12, the filing of an IND application, and the presentation of data from our Phase 1b for ATR-04, the IND filing for ATR-01, the timing of having a signed license agreement with Bayer, and statements about our clinical and pre-clinical programs, and corporate and clinical/pre-clinical strategies.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1b trial for ATR-12 and pre-clinical studies of other product candidates and obtain required approval before commercialization; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described in its registration statement on Form S-1, which is on file with the SEC, and in its most recent annual report on Form 10-K to be filed with the SEC. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Condensed Consolidated Statement of Operations Audited | |||||||||
|
|
| |||||||
| 2023 | 2022 |
| ||||||
Service revenue – related party | $ | 686,000 |
|
| $ | 284,000 |
|
| |
Total revenue |
| 686,000 |
|
|
| 284,000 |
|
| |
|
|
|
|
| |||||
Operating expenses: |
|
|
|
| |||||
General and administrative |
| 4,493,332 |
|
|
| 3,639,666 |
|
| |
Research and development |
| 3,809,063 |
|
|
| 6,097,938 |
|
| |
Total operating expenses |
| 8,302,395 |
|
|
| 9,737,604 |
|
| |
|
|
|
|
| |||||
Loss from operations |
| (7,616,395 | ) |
|
| (9,453,604 | ) | ||
|
|
|
|
| |||||
Non- operating income (expense): |
|
|
|
| |||||
Interest income |
| 1,577 |
|
|
| 4,818 |
|
| |
Interest expense |
| (167,726 | ) |
|
| (251,891 | ) |
| |
Employee retention credit |
| - |
|
|
| 229,813 |
|
| |
Other income |
| - |
|
|
| 65,849 |
|
| |
Forgiveness of accounts payable |
| 56,285 |
|
|
| - |
|
| |
Change in fair value of convertible note |
| (3,630,100 | ) |
|
| (1,250,000 | ) |
| |
Other income (expense) |
| 89,886 |
|
|
| (25,351 | ) |
| |
Total non-operating expenses |
| (3,650,078 | ) |
|
| (1,226,762 | ) |
| |
|
|
|
|
| |||||
Loss before income taxes |
| (11,266,473 | ) |
|
| (10,680,366 | ) |
| |
|
|
|
|
| |||||
Income tax benefit (expense) |
| (17,308 | ) |
|
| - |
| ||
|
|
|
|
| |||||
Net loss | $ | (11,283,781 | ) |
|
| (10,680,366 | ) |
| |
Dividends on preferred stock |
| (1,355,347 | ) |
|
| (2,768,984 | ) |
| |
Net loss attributable to common shareholders | $ | (12,639,128 | ) |
|
| (13,449,350 | ) |
| |
Net loss per Share, basic and diluted |
| (1.83 | ) |
|
| (12.74 | ) |
| |
Weighted average common stock outstanding, basic and diluted | $ | 6,924,453 |
|
| $ | 1,055,399 |
|
|
Condensed Consolidated Balance Sheets Audited | |||||||||
|
| ||||||||
| December 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
Assets |
|
| |||||||
Current Assets: |
| ||||||||
Cash and cash equivalents | $ | 1,795,989 |
| $ | 3,492,656 |
| |||
Other receivables |
| 223,474 |
|
| 266,208 |
| |||
Prepaid expenses and other current assets |
| 516,116 |
|
| 377,019 |
| |||
Total current assets | $ | 2,535,579 |
| $ | 4,135,883 |
| |||
Property and equipment, net |
| 710,075 |
|
| 846,958 |
| |||
Other assets |
| 1,869,832 |
|
| 2,184,602 |
| |||
Total assets | $ | 5,115,486 |
| $ | 7,167,443 |
| |||
Liabilities, preferred stock, and stockholders’ equity |
| ||||||||
Current liabilities: |
| ||||||||
Accounts payable | $ | 897,272 |
| $ | 784,687 |
| |||
Current financing lease liability |
| 14,600 |
|
| - |
| |||
Current operating lease liability |
| 307,655 |
|
| 287,384 |
| |||
Accrued expenses |
| 383,668 |
|
| 993,961 |
| |||
Contract liabilities |
| - |
|
| 156,000 |
| |||
Total current liabilities |
| 1,603,195 |
|
| 2,222,032 |
| |||
Long-term financing lease liability |
| 26,169 |
|
| - |
| |||
Long-term operating lease liability |
| 537,523 |
|
| 840,896 |
| |||
Warrant liability |
| 35,453 |
|
| 70,283 |
| |||
Convertible notes payable, net |
| 0 |
|
| 6,600,000 |
| |||
Total liabilities |
| 2,202,340 |
|
| 9,733,211 |
| |||
Stockholders’ equity (deficit) |
| ||||||||
Preferred stock |
| 0 |
|
| 33,694,542 |
| |||
Common stock |
| 1,210 |
|
| 104 |
| |||
Additional paid-in capital |
| 51,510,269 |
|
| 1,054,138 |
| |||
Accumulated deficit |
| (48,598,333 | ) |
| (37,314,552 | ) | |||
Total stockholders’ equity (deficit) |
| 2,913,146 |
|
| (36,260,310 | ) | |||
Total liabilities, preferred stock and stockholders’ equity (deficit) | $ | 5,115,486 |
| $ | 7,167,443 |
|
Last Trade: | US$0.49 |
Daily Change: | -0.02 -4.84 |
Daily Volume: | 71,319 |
Market Cap: | US$3.700M |
October 29, 2024 September 24, 2024 September 18, 2024 September 06, 2024 August 28, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB